Abstract:Medline (MDLN.O) jumps 41% on its Nasdaq debut, sparking strong investor interest. Trade Medline shares easily with FXPro as the stock gains global attention.

Medline (MDLN.O) made a remarkable debut on the Nasdaq, soaring 41% on its first day of trading and setting the pace for what is being hailed as 2025s most successful IPO so far. The companys public market entry underscored strong investor demand for healthcare and industrial leaders, even as broader markets remain uncertain.
The IPO attracted significant attention from institutional and retail investors, driving early gains and solidifying Medlines position as a major player to watch in the year ahead. Analysts note that this performance signals renewed confidence in companies rooted in tangible fundamentals, rather than purely tech-driven valuations.
Founded over five decades ago, Medline is among the worlds leading suppliers of medical and surgical products. Its extensive catalog spans everything from everyday consumables to advanced healthcare equipment, supporting hospitals and clinics worldwide.

In an era dominated by tech IPOs, Medlines strong market reception reaffirms the enduring appeal of resilient, essential industries. Its robust business foundation and consistent demand from the healthcare sector provide a stable outlook for investors seeking long-term value.
FXPro now offers traders access to Medline shares, allowing participation in post-IPO movements as the stock finds equilibrium. Through FXPro, investors can:
FXPro continues to expand its share offerings, adding new listings and major IPOs as they go public. Medlines promising start makes it a compelling addition for traders looking to capitalize on the 2025 IPO wave.
CFDs and Spread Betting are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading these products. Please ensure you understand the risks before trading.
FXPro is a leading global broker known for its advanced trading platforms, competitive spreads, and access to a wide range of markets, including stocks, commodities, and major IPOs.


Foreign exchange trading is basically of two types: Direct Market Access (DMA) and Over the Counter (OTC). Both come with their own pros and cons. It’s important to understand these two concepts before figuring out the differences between them. In this article, we will explain all of these.

IG review for India in 2026: see the RBI Alert List entry, overseas regulation, login checks, forex limits, and a clear broker safety checklist.

Orbex, a Cyprus-based brokerage entity, has recorded 30 exposure complaints on WikiFX, a leading forex broker regulation inquiry tool, so far. Other review websites have also recorded a healthy number of complaints against the brokerage firm. These complaints largely talk about the alleged profit confiscations by the broker in the name of trading violations, difficulty in accessing fund withdrawals, capital losses due to artificial slippage, etc. In this Orbex review, we have investigated user complaints and provided a regulatory overview of the broker.

FCA warns Swift TradeX in a notice first published and updated on 1 September 2026. The UK Financial Conduct Authority says the firm may be providing or promoting financial services without permission, is not authorised, and may be targeting people in the UK. The notice names the website swifttradexai.com, a Worcester address and a UK telephone number, but also cautions that unauthorised businesses may use incorrect or borrowed contact details. The confirmed issue is authorisation status—not a court finding about every transaction. Anyone considering a payment should stop, verify the firm independently, and avoid using contact information supplied by the platform itself.